Mesoblast files 6-K on director interest change

Mesoblast Limited, an Australia-based company, submitted a Form 6-K for September 2025 to update U.S. investors about a corporate disclosure made in its home market.

Rhea-AI Filing Summary

Mesoblast Limited, an Australia-based company, submitted a Form 6-K for September 2025 to update U.S. investors about a corporate disclosure made in its home market. On September 12, 2025, the company filed a new issue announcement and a change of director’s interest notice (Appendix 3Y) with the Australian Securities Exchange, and this Appendix 3Y is attached to the Form 6-K as Exhibit 99.1.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Mesoblast Limited (MEOBF) report in its September 2025 Form 6-K?

Mesoblast Limited reports that it filed a new issue announcement and a change of director’s interest notice (Appendix 3Y) with the Australian Securities Exchange. This Appendix 3Y is attached as Exhibit 99.1 to the Form 6-K for U.S. investors.

What is attached as Exhibit 99.1 to Mesoblast’s September 2025 Form 6-K?

Exhibit 99.1 contains an Appendix 3Y of Mesoblast Ltd dated September 12, 2025. Appendix 3Y is a change of director’s interest notice filed with the Australian Securities Exchange and is incorporated into the Form 6-K by reference.

When did Mesoblast Limited file the Appendix 3Y referenced in the Form 6-K?

Mesoblast Limited filed the Appendix 3Y, described as a change of director’s interest notice, with the Australian Securities Exchange on September 12, 2025. The same document is attached to the Form 6-K as Exhibit 99.1 for U.S. market disclosure.

Who signed the Mesoblast Limited September 2025 Form 6-K?

The Form 6-K was signed on behalf of Mesoblast Limited by Paul Hughes, who is identified as the Company Secretary. The dated signature line shows September 12, 2025, confirming authorization of the filing under the Securities Exchange Act of 1934.

Which SEC form does Mesoblast Limited use for its ongoing U.S. reporting?

The filing indicates that Mesoblast Limited files annual reports under cover of Form 20-F rather than Form 40-F. This clarifies the company’s chosen reporting framework as a foreign private issuer in the United States securities markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/15/2025 - 07:45 AM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On September 12, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, change of director’s interest notice (Appendix 3Y) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Paul Hughes

Paul Hughes

Company Secretary

Dated: September 12, 2025

INDEX TO EXHIBITS

Item
99.1						Appendix 3Y of Mesoblast Ltd, dated September 12, 2025.